Loading clinical trials...
Loading clinical trials...
MTX228 has been identified as a medication that might allow the re-growth of insulin producing beta cells in people with Type 1 Diabetes. Promoting the re-growth of lost beta cells would be beneficial...
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
University of Alberta
NCT07224321 · Type 1 Diabetes Mellitus
NCT07051005 · Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus (T2DM)
NCT07461805 · Type 1 Diabetes Mellitus
NCT02734277 · Type 1 Diabetes Mellitus, T1DM, and more
NCT06575426 · Diabetes Mellitus, Type 1, Hypoglycemia, and more
University of Alberta
Edmonton, Alberta
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions